mojo doesn't pick sides. mojo picks data.
GLP-1s are lower barrier, reversible, and work well. Gastric bypass or sleeve is higher commitment but shows stronger cardiovascular protection for the right patient.
If you're BMI 35+ with cardiovascular risk factors, this study is worth bringing to your next doctor's appointment.
Until now, surgery and GLP-1s each had their own evidence base. Nobody compared them directly.
That's a big gap when patients are choosing between "a needle" and "the OR." More data = better decisions.
Mayo Clinic just published the first head-to-head comparison of bariatric surgery (gastric bypass, sleeve gastrectomy) vs GLP-1 meds on cardiovascular outcomes.
Both work. Surgery showed greater long-term risk reduction.
Published in Annals of Surgery. First time anyone's put these two treatments on the same scoreboard.
GLP-1 is an accelerator. Not an autopilot.
Think of it as a multiplier for your habits.
Medication (100) × Habits (0) = 0.
Rely entirely on the shot, and you're just losing muscle and borrowing time before the weight comes back.
Start small:
• Eat protein and fiber first
• Save carbs for last
• Take a 10-minute walk after meals
The medication amplifies the effort. Use mojo to log your baseline and watch the changes compound.
Now, NIDA is funding a clinical trial to see if tirzepatide can actually treat cannabis use disorder.
These meds aren't just managing weight. They're turning off the constant cravings for dopamine.
What random craving completely vanished for you since starting?
GLP-1s are quietly rewiring the $40 billion U.S. cannabis market.
The target is the munchies.
Post-cannabis hunger drives a massive chunk of dispensary sales. But GLP-1 users are noticing something strange. The urge just vanishes.
Not "I ate less." The craving never shows up.
Dispensaries are reacting. New York's Stoops NYC just shifted its product lineup to low-dose edibles and vapes. Not by choice. Their customers changed.
